Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at

Share Article adds “Nintedanib (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store. This report focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market.

Nintedanib Colorectal Cancer Market

Nintedanib Colorectal Cancer Market

The report “Nintedanib (Colorectal Cancer) – Forecast and Market Analysis to 2023” focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market. Stivarga is a drug which is used in the treatment of colon or rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally available anti-VEGF inhibitor, for the treatment of refractory CRC in the US, Europe, and Japan. The drug is being investigated in a placebo-controlled, double-blind, randomized Phase III study in 764 metastatic CRC patients. To be eligible for the trial, patients must be refractory to multiple previous treatments for metastatic disease, including 5-FU, oxaliplatin, irinotecan, Avastin or Zaltrap, and anti-EGFR therapy if KRAS wild-type. Previous treatment with Stivarga is allowed. The trial has a primary endpoint of PFS, with secondary endpoints including OS, ORR, and disease control. The trial is due to report data for PFS in the second half of 2016. Complete Report is Available @ .

Nintedanib is an anti-cancer drug which is used for treating colorectal cancer. It is administered orally as well as intravenously. Nintedanib is a tyrosine-kinase inhibitor which targets platelet derived growth factor receptor, vascular endothelial growth factor receptor and fibroblast growth factor receptor. The drug inhibits the formation of blood vessels in and around the tumors, which leads to cells shrinkage and death. The drug starves the tumor cells of nutrients and oxygen, resulting in cell death. Side effects of nintedanib are decreased appetite, weight loss, nausea, headache and stomachache.

Reasons to Buy

  •     Understand and capitalize by identifying products that are most likely to ensure a robust return
  •     Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
  •     Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  •     Make more informed business decisions from insightful and in-depth analysis of Nintedanib performance
  •     Obtain sales forecast for Nintedanib from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Order a Purchase copy of report @ .

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Clinical Staging
3.3 Symptoms

4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening and Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice

5 Competitive Assessment
5.1 Overview

6 Unmet Need and Opportunity
6.1 Overview
6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity

7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development

8 Nintedanib (BIBF-1120)
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical and Commercial Positioning
8.6 SWOT Analysis
8.7 Forecast

9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Colorectal Cancer Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 General Pricing Assumptions
9.4.4 Average Body Weight and Surface Area Across the 8MM
9.4.5 Generic Erosion
9.4.6 Pricing of Pipeline Agents
9.5 Primary Research - KOLs Interviewed for this Report
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

List of Tables
Table 1: TNM and Staging Classification System for CRC
Table 2: Symptoms of Colorectal Cancer
Table 3: Treatment Guidelines for CRC
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
Table 6: Leading Treatments for CRC, 2014
Table 7: Unmet Need and Opportunity in CRC
Table 8: Product Profile - Nintedanib
Table 9: Nintedanib SWOT Analysis, 2014
Table 10: Global Sales Forecasts ($m) for Nintedanib, 2013-2023
Table 11: Average Body Weight and Surface Area Across the 8MM
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: CRC - Phase III Pipeline
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2013-2023
Figure 3: Clinical and Commercial Positioning of Nintedanib

Explore more reports on Cancer Drugs industry at .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
Follow >
Market Reports China
Like >
Follow us on
Visit website